Evidence map›Paper›PMID 41389316›Full record

ArticleCA: a cancer journal for clinicians

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B Atkins, Rick Bangs, Kathryn E Beckermann, Joaquim Bellmunt and 44 more

Erratum issuedAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

54 authors.

Rana R McKayDepartment of Medicine, Urology, and Radiation Medicine and Applied Sciences, University of California-San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-0581-7963
Sumanta PalDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Wanling XieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-5995-8000
David AggenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0003-3963-5751
Laurence AlbigesDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.ORCID https://orcid.org/0000-0002-5734-3480
Andrea ApoloGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-9409-1836
Michael B AtkinsDepartment of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.ORCID https://orcid.org/0000-0003-3901-9924
Rick BangsBladder Cancer Advocacy Network, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-0706-8775
Kathryn E BeckermannDepartment of Medicine, Tennessee Oncology, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-4616-6140
Joaquim BellmuntDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-2328-3421
Stephanie A BergDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6193-5350
Mehmet A BilenDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-4003-1103
David BraunSection of Medical Oncology, Department of Medicine, Yale Cancer Center, Yale University, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0003-4543-5553
Maria I CarloDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-4786-7408
Jason EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0996-0350
Matthew GalskyDivision of Hematology and Medical Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID https://orcid.org/0000-0001-7655-9378
Petros GrivasDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-3965-3394
Shilpa GuptaDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Naomi HaasDivision of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-8907-7968
A Ari HakimiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-0930-8824
Hans HammersDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0002-6224-4559
Daniel Y C HengDepartment of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada.
Michelle HirschDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8767-8564
Gopakumar IyerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Eric JonaschDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-0943-2806
Vadim S KoshkinDivision of Hematology/Oncology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-2277-8668
Oleksandr KryvenkoDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Bryan LewisKidneyCan, Philadelphia, Pennsylvania, USA.
Roger LiDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0003-1274-7200
Surena MatinDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-1638-1445
Benjamin MaughanDivision of Medical Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-0010-8551
David F McDermottDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-2675-5095
Bradley McGregorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8298-0289
Joshua MeeksDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-8535-5545
Matthew MilowskyDivision of Medical Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-8965-8129
Robert MotzerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0001-6925-2327
Andrea NecchiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-3007-2756
Dan PetrylakSection of Medical Oncology, Department of Medicine, Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
Sima PortenDivision of Hematology/Oncology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-3948-4968
Thomas PowlesDepartment of Medical Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0001-7760-4724
Brian RiniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-2212-080X
Brian ShuchDepartment of Urology, University of California-Los Angeles, Los Angeles, California, USA.
Arlene Siefker-RadtkeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6328-9599
Guru SonpavdeDepartment of Genitourinary Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA.ORCID https://orcid.org/0000-0002-1010-9611
S Srikala SridharDivision of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-6994-1285
Cristina SuarezDepartment of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Chad TangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-5915-1327
Abhishek TripathiDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Michiel S Van Der HeijdenDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-4407-7881
Martin VossDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Wenxin XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8450-2037
Tian ZhangDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jonathan RosenbergDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID https://orcid.org/0000-0003-2637-4249
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9201-3217

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence-based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus-building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as >90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3-pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum-based chemotherapy postprogression in biomarker-negative UTC. For RCC, there was consensus on the role of single-agent vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence-informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsUrologic NeoplasmsAntibodies, Monoclonal, HumanizedHumansNeoadjuvant TherapyAntibodies, Monoclonal, HumanizedpembrolizumabDelphi processexpert panel consensusrenal cell carcinomatreatment optimizationurothelial carcinoma

Identifiers

PMID41389316
PMCPMC12701758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.